Cover Image
Market Research Report
Product code 
245961

Spinocerebellar Ataxia (SCA) - Drugs in Development, 2021

Published: | Global Markets Direct | 113 Pages | Delivery time: 1-2 business days

Price

Back to Top
Spinocerebellar Ataxia (SCA) - Drugs in Development, 2021
Published: September 30, 2021
Global Markets Direct
Content info: 113 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia - Drugs In Development, 2021, provides an overview of the Spinocerebellar Ataxia (Genetic Disorders) pipeline landscape.Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Spinocerebellar Ataxia (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 3, 12 and 8 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

Spinocerebellar Ataxia (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinocerebellar Ataxia (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC13080IDB

Table of Contents

Table of Contents

  • Introduction
  • Spinocerebellar Ataxia (SCA) - Overview
  • Spinocerebellar Ataxia (SCA) - Therapeutics Development
  • Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
  • Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
  • Spinocerebellar Ataxia (SCA) - Drug Profiles
  • Spinocerebellar Ataxia (SCA) - Dormant Projects
  • Spinocerebellar Ataxia (SCA) - Discontinued Products
  • Spinocerebellar Ataxia (SCA) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Spinocerebellar Ataxia (SCA), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Anima Biotech Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Annji Pharmaceutical Co Ltd, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by BioXcel Corp, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Celavie Biosciences LLC, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Corestem Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Dystrogen Therapeutics SA, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Enzerna Biosciences LLC, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Everfront Biotech Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Exicure Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Gene Therapy Research Institution Co Ltd, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by IntraBio Ltd, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Lacerta Therapeutics Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Locanabio Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Novartis AG, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by PTC Therapeutics Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Sclnow Biotechnology Co Ltd, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Seelos Therapeutics, Inc., 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Steminent Biotherapeutics Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Triplet Therapeutics Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by UniQure NV, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Vico Therapeutics BV, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, 2021
  • Spinocerebellar Ataxia (SCA) - Pipeline by Wave Life Sciences Ltd, 2021
  • Spinocerebellar Ataxia (SCA) - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Spinocerebellar Ataxia (SCA), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021